News Hyundai Bioscience Co., Ltd.

Equities

A048410

KR7048410005

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
21,100 ^KRW	+1.44%		+2.18%	-19.16%

Apr. 25	Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil	CI
Apr. 25	Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil	Apr. 25	CI
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer	Apr. 25	CI
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer	Apr. 22	CI
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection	Apr. 19	CI
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.	Mar. 10	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Vector Inc. completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd.	23-08-30	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Vector Inc. agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. for KRW 13.7 billion.	22-08-24	CI
Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA	22-05-25	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials	22-05-12	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills	21-12-29	MT
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Hyundai Bioscience Co., Ltd. Announces Oral Antiviral Drug from Korea May Be A Problem Solver for Covid-19	21-05-13	CI
Hyundai Bioscience Announces CNPharm Publishes a Research Paper on Successful Repurposing of Niclosamide for COVID-19 Treatment by Using a Drug Delivery System	21-04-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Hyundai Bioscience Co., Ltd.

Equities

A048410

KR7048410005

Summary

Filters